Biogen and Evotec sign deal
World News | September 09, 2009
PharmaTimes
Biogen Idec has joined forces with small molecule drug developer Evotec to identify promising molecules.
Under the terms of the agreement, Evotec’s technologies will be used in protein production, assay development and high throughput screening to identify molecules for Biogen.
There is the option to screen further targets as agreed. No financial details were disclosed.
The deal comes hours after the news that Biogen’s takeover bid of Facet was rejected.
Click here to order a reprint of this news story.
Tags
screening
assay development
Biogen Idec and Evotec
small molecule
protein production
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.